Product/Composition:- | Ciprofolxacin Suspension |
---|---|
Strength:- | 100 mg/5 mL, 200 mg/5 mL |
Form:- | Oral Suspension |
Reference Brands:- | Cipro(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ciprofloxacin suspension inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and bacterial growth. It effectively treats urinary, respiratory, and gastrointestinal infections. Benefits include rapid absorption, broad-spectrum activity, and suitability for pediatric use, providing reliable, targeted infection control with convenient oral administration when used properly.
Ciprofloxacin suspension is approved in the EU and US for treating urinary, respiratory, and gastrointestinal infections, especially in pediatric patients. In the EU, brands like Cipro are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data, with generic formulations available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans, for approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ciprofloxacin suspension, ensuring adherence to European and US standards for safe, effective antibiotic therapy.